{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05757700",
            "orgStudyIdInfo": {
                "id": "22-401"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma",
            "officialTitle": "A Phase I Study of T-cell Receptor Alpha Constant (TRAC) Locus Integrated CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With CD19+ Relapsed or Refractory Large B-Cell Lymphoma",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology"
            ],
            "study": "study-of-trac-chimeric-antigen-receptor-car-t-cells-in-people-with-b-cell-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2023-02-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-23",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02-23",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-24",
            "studyFirstSubmitQcDate": "2023-02-24",
            "studyFirstPostDateStruct": {
                "date": "2023-03-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Takeda",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants."
        },
        "conditionsModule": {
            "conditions": [
                "B-Cell Lymphoma",
                "Large B-cell Lymphoma",
                "DLBCL, Nos Genetic Subtypes",
                "High-grade B Cell Lymphoma",
                "Mediastinal Large B-cell Lymphoma"
            ],
            "keywords": [
                "B-Cell Lymphoma",
                "Large B-cell Lymphoma",
                "DLBCL",
                "High-grade B cell lymphoma",
                "Mediastinal Large B-cell Lymphoma",
                "TRAC-CAR T cells",
                "Memorial Sloan Kettering Cancer Center",
                "22-401"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma",
                    "type": "EXPERIMENTAL",
                    "description": "Participants have histologically confirmed DLBCL and large B cell lymphoma. Participants will be treated with escalating doses of modified T cells.",
                    "interventionNames": [
                        "Biological: 19(T2)28z1xx TRAC T cell"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "19(T2)28z1xx TRAC T cell",
                    "description": "Participants will be treated with escalating doses of modified T cells.\n\nDose level -1: 3 x 10\\^6 Dose level 1: 10 x 10\\^6 Dose level 2: 30 x 10\\^6 Dose level 3: 100 x 10\\^6",
                    "armGroupLabels": [
                        "Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum tolerated dose (MTD)",
                    "description": "The target toxicity rate for the MTD is",
                    "timeFrame": "up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years of age\n* Creatinine \u22641.5 mg/100 ml or creatinine clearance \u2265 45ml/min/m2 , direct bilirubin \u22642.0 mg/100 ml, AST and ALT \u22643.0x upper limit of normal (ULN)\n* Adequate pulmonary function as assessed by \u226592% oxygen saturation on room air by pulse oximetry.\n* Histologically confirmed DLBCL and large B cell lymphoma, including\n\n  * DLBCL, not otherwise specified (NOS), or\n  * Transformed DLBCL from follicular lymphoma, or\n  * High-grade B cell lymphoma (excluding Burkitt's lymphoma), or\n  * Primary mediastinal large B cell lymphoma\n\nAND\n\n* Chemotherapy refractory disease, defined as a failure to achieve at least a partial response or disease progression within 12 months to the last therapy, OR\n* Disease progression or recurrence in \u226412 months of prior autologous stem cell transplant (ASCT), OR\n* Relapsed disease after 2 or more prior chemoimmunotherapies with at least one containing an anthracycline and CD20 directed therapy\n\n  * Patients need to have radiographically documented disease\n\nExclusion Criteria:\n\n* ECOG performance status \u22652.\n* Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.\n* Active CNS disease\n* Impaired cardiac function (LVEF \\<40%) as assessed by ECHO or MUGA scan.\n* Patients with the following cardiac conditions will be excluded:\n\n  * New York Heart Association (NYHA) stage III or IV congestive heart failure\n  * Myocardial infarction \u22646 months prior to enrollment\n  * History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration \u22646 months prior to enrollment\n* Patients with HIV or active hepatitis B or hepatitis C infection are ineligible.\n* Patients with prior allogeneic hematopoietic stem cell transplant are eligible, if more than 3 months from transplant and if patients have no active graft versus host disease (GvHD) and not on systemic immunosuppressive therapy.\n* Prior CD19-directed therapy including commercially approved or investigational CD19 CAR T cells or BiTEs is allowed, as long as expression of CD19 is confirmed by flow cytometry or immunohistochemistry.\n* Patients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligible.\n* Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin.\n* Patients with presence of clinically significant neurological disorders such as epilepsy, generalized seizure disorder, severe brain injuries are ineligible.\n* Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jae Park, MD",
                    "role": "CONTACT",
                    "phone": "646-608-3743",
                    "email": "parkj6@mskcc.org"
                },
                {
                    "name": "M. Lia Palomba, MD",
                    "role": "CONTACT",
                    "phone": "646-608-3711",
                    "email": "Palombam@MSKCC.ORG"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jae Park, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center (All Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jae Park, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3743"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}